Athyrium Capital Management has acquired uMotif
Athyrium Capital Management, the New York-based investment firm, has acquired uMotif. The new funding will support the continued scale-up of uMotif’s unique patient-first software platform for clinical research.
Catalysed by the Covid pandemic, the life sciences industry is increasingly adopting digital approaches for clinical and real-world research, including decentralisation of trials. uMotif’s unique software is available from app stores on any device and is designed to provide pharmaceutical, biotech, medtech and Contract Research Organisation (CRO) clients with the most engaging patient data capture experience. By focusing on high quality design and modern cloud-native software, uMotif delivers high rates of data capture, patient retention, data quality and delivery speed – ultimately helping achieve faster, better trials. In an immunology study, uMotif’s software engaged and retained participants so effectively, that the data capture timelines were reduced by 33%, generating new insights faster.
The company continues to be supported by its existing investors AlbionVC and DNV, which led a Series A investment round in 2020. The new investment supports further international expansion and continued development of world-leading technologies, including unique and patent-protected solutions for pain, clinical outcome and symptom tracking. Having entered the US in 2021, and with support of a US-based healthcare investor, uMotif’s North American team will significantly grow – including in sales, marketing and service delivery. This growth takes place alongside a continued focus on developing the industry’s most patient-centric technology. uMotif works closely with partners to offer trial sponsors a seamless, beautiful and engaging patient-first experience to power site-based and decentralised trials.
Rothschild & Co advised on the acquisition of this transaction. For further detail please contact Karen Dawaf.